Supplementary Table S1 from Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR&lt;sup&gt;+&lt;/sup&gt; Early-stage Breast Cancer for 10 Years of Endocrine Therapy